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Letters to the EditorIndustrial, not fruit fructose intake is associated with the severity
of liver ﬁbrosis in genotype 1 chronic hepatitis C patientsMost importantly however, is the lack of a plausible explana-
tion given by the authors as to why the speciﬁc source of fructose,
whether from ‘natural’ apples or ‘industrial’ cola, would have an
impact on liver ﬁbrosis rather than the degree of consumption of
the monosaccharide itself. Indeed, fructose is the same com-
pound regardless of the source, with ‘industrial’ derived fructose
unlikely to have a differential unfavorable impact on caloric
intake and metabolic proﬁle. A more credible explanation is that
those who have higher ‘industrial’ fructose intake are likely to
have a less healthy diet and lifestyle, resulting in higher rates
of obesity and insulin resistance. Our suggestion is that the key
ﬁndings of this study are likely to represent a confounding rela-
tionship, brought about by gaping methodologic ﬂaws. Our view-
point is further supported by the independent association
between ‘industrial’ fructose intake and obesity that the study
describes.
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In their study recently published in the Journal of Hepatology, Pet-
ta et al. reported an independent association between advanced
liver ﬁbrosis in chronic hepatitis C virus (HCV) genotype 1 infec-
tion and ‘industrial’, but not fruit fructose intake [1]. While these
ﬁndings are novel we believe this cross-sectional study has sig-
niﬁcant limitations that need to be addressed before the results
can be applied to the broader HCV community.
Firstly, the use of an American web-based calculator
(www.health-diet.us/fructose) to quantify the fructose content
of speciﬁc foods requires validation in an Italian population
consuming locally produced and marketed food. The United
States uses high fructose corn syrup as an additive sweetener
to food and carbonated beverages to a much higher extent
than many other countries. Hence the methodology used to
calculate ‘industrial’ fructose intake may have resulted in sig-
niﬁcant bias being introduced into the study. The authors have
not given any speciﬁc information of the use of high fructose
corn syrup as a sweetener in Italy, but solely relied on extrap-
olation from American data and practices. Furthermore, the
methodology of use of a three-day food diary is questionable
when the progression of ﬁbrosis in HCV infection occurs over
years.
Secondly, the very low overall fructose intake by study partic-
ipants (18.0 ± 8.7 g/day) limits the generalizability of the study.
This low value is likely reﬂective of the regional dietary differ-
ences many Italians have when compared with other developed
countries, including the United States of America. National die-
tary intake survey data shows that >95% of American residents
consume <100 g of fructose per day from all sources [2], while
Australian adults consume <60 g total fructose per day [3]. These
values are markedly higher than this study’s population. More-
over, as those with advanced ﬁbrosis only had 2.3 g higher mean
intake of ‘industrial’ fructose per day than those without
advanced ﬁbrosis and the clinical relevance of such a small
increase in this form of fructose is questionable.
Thirdly, this study did not ﬁnd any relationship between insu-
lin resistance and advanced ﬁbrosis. Insulin resistance is a marker
of glycaemic control and has been identiﬁed by a number of inves-
tigators, including Petta’s group, to be an important cofactor in the
development of advanced liver ﬁbrosis in genotype 1 infection
[4–7]. The lack of an association between insulin resistance and
advanced ﬁbrosis, as well as steatosis, in both univariate and mul-
tivariate analysis in this study cohort raises concern about the
internal validity of the study’s ﬁndings. Of particular note diabe-
tes, insulin resistance, HOMA score, blood glucose levels, insulin
levels, bodymass index, and other anthropometricmeasures were
not included in the same multivariate analysis. The authors state
that this method was employed to ‘avoid colinearity’, but their
statistical methodology may explain why no association between
insulin resistance and ﬁbrosis was seen.
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Reply to: ‘‘Industrial, not fruit fructose intake is associated with
the severity of liver ﬁbrosis in genotype 1 chronic hepatitis C
patients’’
Fructose intake and liver damage in chronic hepatitis C
To the Editor:
Prof. Kitson’s comments give us the opportunity to clarify some
issues that were not completely dealt with in our manuscript.
In the study we reported a link between fructose intake and
the severity of liver ﬁbrosis in a cohort of Italian patients with
genotype 1 chronic hepatitis C (CHC) [1], with an association
found for industrial, but not for fruit fructose intake. Our results
were in keeping with data already reported in patients with non-
alcoholic fatty liver disease [2,3].
Prof. Kitson and his colleagues question ﬁrstly the appropri-
ateness of using a web-based calculator of U.S. origin
(www.healthdiet.us/fructose) to assess fructose intake in the
Italian population, due to a presumed much lower fructose
consumption in the latter. Actually, we considered industrial
fructose as any amount of fructose derived from food sources
containing high fructose corn syrup (beverages like soft drink
and fruit juices, processed foods like fast-food, especially when
enriched with industrial sauces). The U.S. database for the cal-
culation of fructose intake is most likely valid also for use in
Italian patients, since the majority of foods and beverages with
added fructose are produced by multinational companies, and
the concentration of fructose does not change among countries.
In addition, our data on fructose consumption are in keeping
with another Italian report [4]. Prof. Kitson and colleagues also
question the validity of a three-day food diary. It has been
reported that a three-day diary record correlates closely with
a longer 9-day diary [5], providing a solid dietary assessment.
In a cross-sectional analysis no inference can be made regard-
ing a possible causal relationship, but this possibility may
be postulated. We have simply described the positive associa-
tion between industrial fructose and advanced ﬁbrosis, but
the two conditions might also share common pathogenic
mechanisms.
As a second point, our study was performed in an Italian pop-
ulation, not in an Australian or U.S. population, where much
higher rates of fructose consumption are recorded. The accuracy
of our computation of fructose intake is in keeping with the
industrial fructose intake reported in the Italian population [4],
but lower than in the U.S. population. In the participants of
the LOOK Ahead study consuming P15 g/day of fructose
(high-fructose consumers), a fructose challenge identiﬁed
metabolic abnormalities potentially responsible for NAFLD
progression [6]. This threshold was observed in most of our cases
with ﬁbrosis, and the higher industrial fructose intake was the
major source of difference between cases with advanced vs. mild
hepatic ﬁbrosis. When industrial fructose intake as continuous
variable was replaced in the model by industrial fructose
as categorical variable, 14/25 patients consuming P8 g/day
industrial fructose had F3-F4 ﬁbrosis vs. 18/89 in the group with
lower intake (p = 0.01).
Thirdly, Kitson et al. remark the lack of association between
severe liver ﬁbrosis and both insulin resistance (IR) and steatosis
in this speciﬁc population. In the present series, steatosis was
linked to ﬁbrosis at both univariate and multivariate analysis.
Both IR and steatosis, the phenotypic hepatic expression of IR,
are risk factors for ﬁbrosis; they both might play an important
role in ﬁbrosis progression and are likely to be variably combined
in different settings [7,8]. As to the possible reason(s) why indus-
trial, not fruit fructose intake, is associated with the severity of
liver ﬁbrosis in CHC, several tentative hypotheses may be
suggested. In fresh fruit the deleterious effects of fructose might
be counterbalanced by the positive effects of other nutrients (e.g.,
ﬁbers) and antioxidants, not present in industrial fructose. In
processed food, the glucose of high-fructose corn syrup might
accelerate fructose absorption, making industrial sugars
unhealthy. Finally, even if the link between industrial fructose
and the clinico-pathological features (i.e., liver ﬁbrosis and obes-
ity) was independent of energy intake on a statistical basis, we
cannot rule out a pivotal role of calories and/or of a less healthy
diet and lifestyle in the reported association, considering that
higher amounts of industrial fructose were associated with
high-calorie diets.
Hence we are conﬁdent that our study provides reliable evi-
dence, albeit of an associative nature. Further research is clearly
needed to provide external validation and to eventually elucidate
the pathophysiological basis, aiming to a healthy diet as an addi-
tional tool to manage patients with HCV-induced chronic liver
disease.
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